AMPEL BioSolutions’ breakthrough precision medicine predicts drug options with RNA analysis and machine learning


CHARLOTTESVILLE, Va.July 6, 2022 /PRNewswire/ — AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could modernize the way physicians treat patients for a wide variety of diseases, including autoimmunity, infectious diseases and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley, California, the industry-leading platform technology uses RNA analysis and machine learning to characterize an individual’s gene expression and provide clinical decision support to physicians for treatment options for their patients. The technology, just a concept from the last few years, is being used to launch a portfolio of more than 10 clinical trials over the next five years to provide decision support for diseases that affect more than 50 million Americans.

AMPEL’s innovative machine learning approach, now ready to be developed as a clinical decision-support biomarker test, could have a major impact on healthcare by enabling physicians to identify the root cause of patients’ disease symptoms and to select the right treatment more accurately. AMPEL’s approach is sensitive enough to detect early signs of disease and to group patients according to the severity of their condition. The application of AMPEL’s technology has helped more than 15 pharmaceutical companies in drug development and clinical trials.

Patients with autoimmune and inflammatory diseases often suffer from unpredictable disease activity that affects daily activities such as work and family life. Since unpredictable symptoms often lead to trips to the emergency room, the ability to predict disease exacerbation and systemic involvement in routine testing has important implications for healthcare and health economics. AMPEL expects to launch the first two products in the coming years, LuGENE® blood tests for lupus and DermaGENE® skin biopsy test for psoriasis, atopic dermatitis, scleroderma, and lupus. In addition, AMEL’s CovGENE® blood test that predicts how severe a disease course a COVID patient may experience and can apply to “long COVID” is ready for license/co-development with a company that already offers diagnostic COVID tests.

Combined with AMPEL’s pipeline of tools for analyzing very large and complex clinical data sets (“Big Data”), AMPEL’s Genomic Platform technology with machine learning is an important step towards implementing routine testing to monitor disease activity. and provide decision support for treatment based on patient gene expression. This will change the way doctors treat patients by using the information gathered by the lab test and analyzed by machine learning to diagnose, characterize the precise molecular abnormalities and treat diseases before damage begins, helping patients become saved from the pain and discomfort of diseases that otherwise drastically affect them. lives.

Pharmaceutical companies are testing drugs in clinical trials and are faced with the challenge of enrolling patients who have the best potential to respond to the treatment being tested. Enrolling the “wrong” patients can lead to trial failure, often leading to the discontinuation of a drug toward FDA approval, which may benefit a subset of the overall patient population. AMPEL’s technology helps pharmaceutical companies proactively identify the patients most likely to respond to specific treatments, helping to improve clinical trial outcomes and quality of life for patients in need. AMPEL’s Pharma work was highlighted by Dr. Peter Lipsky at the Precision Medicine World Conference in a panel highlighting the use of machine learning in patient selection and outcome prediction in clinical trials and by Dr. Amrie Grammer during a Google-Reuters webinar focused on: machine learning approaches to select the right patient for the right study at the right time.

dr. Peter Lipsky, AMPEL Co-Founder, CEO and Chief Medical Officer: “It is very gratifying to see how a concept evolves into a reality that can help patients. When we started several years ago, we thought that analyzing gene expression data could effectively subset patients and use each patient’s molecular profile. to help identify the best treatment for each individual.By adopting new machine learning approaches, we are now ready to launch our first application which we believe should be an important step in helping patients with autoimmune diseases truly precision medicine.”

dr. Amrie Grammer, AMPEL Co-Founder, Chairman and CSO: “Our team has developed a genomic platform technology with machine learning that supports precision clinical medicine testing that predicts drug options based on gene expression. AMPEL is changing the paradigm of treating autoimmune and inflammatory diseases. We are proud to do this work in Virginia and will continue to recruit talent and grow our business here.”

Background information

Machine learning is an analytical technique for training computers to assess information and make predictions. AMPEL has used this approach in a new way to train a computer to analyze data obtained by assessing a type of “Big Data”, namely those obtained by assessing gene expression information, to predict whether a person with lupus, psoriasis, atopic dermatitis, or scleroderma experiences a flare-up of disease activity. Gene expression analysis examines the number and pattern of genes that are expressed at any given time and can provide insight into the entire spectrum of genome aberrations.

Many chronic illnesses have unexpected flare-ups that dramatically affect the patient’s quality of life. Furthermore, treatments for chronic diseases have been developed based on a patient population as a group, so some individuals will respond differently or not at all to available treatments. For the past nine years, AMPEL scientists and clinicians have been working on ways to address this problem, designing concepts to personalize treatments for an individual patient rather than a patient population. Peer-reviewed publications confirm the usefulness of the concept of AMPEL, which is now in the commercialization phase.

AMPEL’s initial focus was lupus, but the test can be used for many autoimmune or inflammatory diseases. AMPEL’s blood and tissue biopsy tests are prognostic and staging biomarkers that will support the physician in making decisions at the time on the most appropriate drugs for the patient.

About AMPEL BioSolutions LLC (2013-present)

AMPEL BioSolutions is a precision medicine company that commercializes a development pipeline of CLIA-certified gene expression tests for blood or tissue samples that provide clinical decision support by determining disease status, identifying the molecular pathway, and predicting drug options. AMPEL’s technology is a cloud-based platform that hosts proprietary RNA analysis tools and machine learning algorithms covered by more than 25 patents filed/pending and more than 80 peer-reviewed publications in high-quality journals. Disease areas for the AMPEL precision medicine test portfolio include systemic lupus erythematosus, psoriasis, scleroderma, atopic dermatitis, lupus nephritis, fibromyalgia, cardiovascular, Sjogren’s syndrome, ASD, wellness, lung cancer and SARS-Cov2. AMPEL’s technology encompasses more than 95% of all known genes and AMPEL’s exclusive curated database of >15,000 individual gene expression profiles with rich clinical information fuels evidence-based machine learning predictions. AMPEL BioSolutions was voted the Coalition for 21st Century Precision Medicine early 2022.

Media contact: Amrie Grammer[email protected]

SOURCE AMPEL BioSolutions

Leave a Comment

Your email address will not be published.